Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years - Concepedia

Concepedia

Publication | Closed Access

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

109

Citations

32

References

2020

Year

Kristi L. Williams, Arangassery Rosemary Bastian, Robert Feldman, Edmund Omoruyi, Els De Paepe, Jenny Hendriks, Hester van Zeeburg, Olivier Godeaux, Johannes P. M. Langedijk, Hanneke Schuitemaker,

The Journal of Infectious Diseases

Abstract

Ad26.RSV.preF (LD and HD) had an acceptable safety profile and elicited sustained humoral and cellular immune responses after a single immunization in older adults.

References

	Year	Citations

Page 1